IDT Biologika Awarded 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases
IDT Biologika, a globally integrated manufacturer of vaccines and biopharmaceuticals, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services, has awarded the company a 10-year Indefinite Quantity, Indefinite Delivery (IDIQ) contract no. HHSN272201800011I to provide process development, manufacturing and characterization of vaccine and biologic products for infectious diseases. The total funding could be up to $80 million over the course of the contract if all project milestones are met.
The NIAID contract, which is based upon performance milestones, will support early research and development projects, including GMP manufacturing of Phase I/II clinical material for inclusion in Investigational New Drug (IND) applications and/or Biologic License Applications (BLA). IDT has initially received $88,900 for administrative, technical and management support activities to be conducted during the first year, May 15, 2018 to May 14, 2019. The exact content and scope of each individual project is still to be determined with NIAID.
“It is a great honor to be awarded this NIAID contract and we are pleased to support the efforts by the United States to develop vaccine countermeasures to address public health threats,” said IDT Biologika Chief Executive Officer Andreas Kastenbauer. “IDT has a long standing history and proven track record of developing and manufacturing bacterial and virus-based vaccines, including fill and finish for international governments and a number of pharmaceutical and biotech companies worldwide. Our state-of-the-art manufacturing facilities located in Dessau and Rockville are well positioned to serve the current and future requirements of NIAID.”
About IDT Biologika
IDT Biologika is an innovative, privately-held company with nearly 100 years of experience in researching, developing, manufacturing and marketing products for the global protection of human and animal health. The company produces vaccines and pharmaceuticals according to the highest quality standards, for its own animal health products and under contract.
Company sites in Germany include the BioPharmaPark in Dessau-Rosslau and the Riems district of Greifswald. IDT's Animal Health business is marketed internationally from its offices in Denmark, the Netherlands, France, Spain, Poland and Canada. In the United States, IDT Corporation operates a production site for clinical test samples in Rockville, Maryland. In Canada, IDT Biologika subsidiary Gallant Custom Laboratories manufactures autogenous vaccines. The same vaccines are produced by the recently acquired IDT subsidiary in the United Kingdom, Ridgeway Biologicals.
IDT Biologika is a member of the Klocke Group, which specializes in contract production and packaging of medications, vaccines and cosmetic products. As a traditional family-owned company, the Klocke Group employs a workforce of more than 2,500 people at 10 production sites and sales offices around the world. For more information, visit www.idt-biologika.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005382/en/